Thor-707 sitc
WebJun 27, 2024 · THOR-707 Q3W at recommended Phase 2 dose (RP2D) with a checkpoint inhibitor via IV administration Q6W will consist of one 9-week cycle of THOR monotherapy on Cycle 1 Day 1 followed by THOR-707 Q3W + checkpoint inhibitor at Cycle 1 Day 22. Subsequently treatment will consist of repeated 6-weeks cycles with combination therapy. WebNov 3, 2024 · The study is a phase 2 non-randomized, open-label, multi-cohort, multi-center study assessing the clinical benefit of SAR444245 (THOR-707) combined with other …
Thor-707 sitc
Did you know?
WebNov 9, 2024 · Synthorx Inc. announced that company researchers will present results of preclinical studies demonstrating the safety and anti-tumor effects of its lead product candidate THOR-707, a Synthorin of... March 12, 2024 WebJul 1, 2024 · Abstract. THOR-707 (SAR444245) is a recombinant human IL-2 molecule that includes a PEG moiety irreversibly bound to a novel amino acid via click chemistry to …
WebOct 29, 2024 · Part 1 of the study will determine the recommended phase 2 dose (RP2D) of THOR-707 as a single agent and part 2 will determine the RP2D of THOR-707 in combination with a PD-1 inhibitor. WebJun 4, 2024 · A Phase 1/2 Non-randomized, Open-label, Multi-cohort, Multi-center Study Assessing the Clinical Benefit of SAR444245 (THOR- 707) Combined With Cemiplimab for the Treatment of Participants With Advanced Unresectable or Metastatic Skin Cancers: Actual Study Start Date : July 15, 2024: Estimated Primary Completion Date : August 22, …
WebNov 9, 2024 · The study, titled "THOR-707: An engineered IL-2 for the treatment of solid tumors with superior preclinical efficacy and safety evidence," investigates the application … WebOct 29, 2024 · THOR-707 is currently being evaluated by Sanofi in an ongoing Phase 1 open-label, multi-center, dose escalation and expansion trial. This study is designed to evaluate …
WebOther names: THOR 707, recombinant human IL-2, IBI-127, SAR'245, SAR444245, THOR-707, not alpha synthorin of IL-2, ... IL-2, as monotherapy and in combination with …
WebJul 5, 2024 · THOR-707 Q3W at recommended Phase 2 dose (RP2D) with a checkpoint inhibitor via IV administration Q6W will consist of one 9-week cycle of THOR monotherapy on Cycle 1 Day 1 followed by THOR-707 Q3W + checkpoint inhibitor at Cycle 1 Day 22. Subsequently treatment will consist of repeated 6-weeks cycles with combination therapy. hydrangea in a pot careWebMar 12, 2024 · Presented Preclinical Data at SITC. In November 2024, Synthorx presented results of preclinical studies demonstrating the safety and anti-tumor effects of THOR … massachusetts sibling support networkWebTHOR 707 - THOR-707, a “not-alpha†Synthorinâ„¢ of interleukin-2 (IL-2), for the treatment of solid tumors at the Society for Immunotherapy of Cancer (SITC) THOR-707, a variant of IL-2, is in development in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor. hydrangea in phoenix azWebLighting up only the immune cells that matter Asher Bio hydrangea in pots winter careWebNov 9, 2024 · Synthorx to Present Preclinical Data for THOR-707, a "Not-Alpha" IL-2 Synthorin, for the Treatment of Solid Tumors at SITC 2024 News provided by. Synthorx, … massachusetts short term disability claimWebMay 26, 2024 · Methods: Using a synthetic biology platform, we have engineered THOR-707, a rIL-2 that contains a novel amino acid encoded in the IL-2 gene via a new DNA base pair (X-Y). The novel amino acid serves as a hook for site specific pegylation that extends half-life, blocks IL-2R⍺ engagement and binds to the IL-2Rβγ. hydrangea in pots sun or shadeWebApr 9, 2024 · In pre-clinical experiments, THOR-707 exhibited the ability to induce the expansion of CD8+T-cells suggesting potential for anti-tumor effects both as single agent … hydrangea in a planter